Hospital
University of Colorado Hospital Authority
University of Colorado Hospital Authority was paid $58.11M by Medicaid between Jan 2018 and Dec 2024, across 401 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoUNIVERSITY OF COLORADO HOSPITAL AUTHORITY
AURORA, CO 80045
AURORA, CO 80045
33aNPI1477531580assigned 01/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$58.11M
24GClaims1,747,184
24DCodes billed401
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#4 of 51
Median peer was paid$1.24M
This provider vs. median47×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CONCORDIA, ELIZABETH controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 309,195 | $7.68M | |
| 2019 | 239,811 | $5.97M | |
| 2020 | 156,540 | $4.78M | |
| 2021 | 228,345 | $7.73M | |
| 2022 | 279,908 | $9.89M | |
| 2023 | 318,857 | $12.79M | |
| 2024incomplete | 214,528 | $9.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 78,705 | 72,026 | $10.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 55,544 | 51,518 | $6.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 56,110 | 51,700 | $6.70M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 22,844 | 19,796 | $5.99M |
| G0378 | Hospital observation service, per hour | 6.1% | 21,803 | 18,501 | $3.53M |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 3.3% | 8,245 | 977 | $1.91M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 3.2% | 8,381 | 4,238 | $1.84M |
| 59025 | Fetal non-stress test | 2.0% | 6,924 | 4,696 | $1.15M |
| 80053 | Comprehensive metabolic panel | 1.9% | 47,752 | 35,877 | $1.12M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 14,372 | 12,580 | $853K |
| 64615 | 1.4% | 4,233 | 3,899 | $797K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 82,311 | 74,107 | $714K |
389 more codes
| 67028 | Intravitreal injection of a pharmacologic agent | 1.2% | 5,239 | $685K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 391 | $537K |
| 0002A | <1% | 6,420 | $533K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,930 | $520K |
| 20610 | <1% | 3,595 | $484K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 137,141 | $428K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 661 | $401K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,011 | $401K |
| 0001A | <1% | 4,734 | $396K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 71,352 | $386K |
| 92134 | <1% | 14,584 | $384K | |
| 31231 | <1% | 1,638 | $344K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 96,434 | $344K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 25,679 | $335K |
| 31579 | <1% | 728 | $304K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 17,152 | $298K |
| 80197 | <1% | 7,776 | $297K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,326 | $295K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,000 | $281K |
| 87536 | <1% | 4,098 | $258K | |
| 92083 | <1% | 3,511 | $247K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,736 | $214K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,477 | $208K |
| 64483 | <1% | 313 | $189K | |
| 81003 | <1% | 11,308 | $187K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,214 | $187K |
| 97803 | <1% | 2,660 | $180K | |
| 93798 | <1% | 2,270 | $170K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,326 | $167K |
| 90715 | <1% | 2,297 | $162K | |
| 36512 | <1% | 301 | $162K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,142 | $156K |
| 90686 | <1% | 4,182 | $150K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 270 | $149K |
| 51798 | <1% | 2,673 | $140K | |
| 84484 | <1% | 5,783 | $138K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,974 | $137K |
| 0004A | <1% | 1,956 | $129K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,312 | $129K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,569 | $120K |
| 86780 | <1% | 5,296 | $117K | |
| 81025 | <1% | 6,302 | $101K | |
| J3490 | Unclassified drugs | <1% | 166,695 | $99K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,663 | $93K |
| 86850 | <1% | 3,567 | $92K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,020 | $92K |
| 92133 | <1% | 3,646 | $91K | |
| 95806 | <1% | 272 | $91K | |
| 85027 | <1% | 15,174 | $88K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,538 | $87K |
| 46607 | <1% | 179 | $82K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 60,229 | $80K |
| 80076 | <1% | 6,638 | $79K | |
| 64405 | <1% | 501 | $77K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 136 | $75K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 804 | $72K |
| 86140 | <1% | 5,256 | $71K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 313 | $70K |
| 83735 | <1% | 8,318 | $69K | |
| 97602 | <1% | 330 | $69K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 9,396 | $69K |
| 86900 | <1% | 3,675 | $68K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,150 | $63K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,194 | $61K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 800 | $60K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 21,482 | $59K |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 29 | $58K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,192 | $57K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 157 | $56K |
| 20553 | <1% | 636 | $56K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 252 | $56K |
| 82105 | <1% | 965 | $55K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 45,469 | $53K |
| 85610 | <1% | 8,685 | $52K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,124 | $50K |
| 94726 | <1% | 240 | $50K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 74 | $47K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 928 | $44K |
| 74183 | <1% | 196 | $44K | |
| 73610 | <1% | 825 | $43K | |
| 87150 | <1% | 1,469 | $43K | |
| 74160 | <1% | 13 | $42K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 221 | $42K |
| 83880 | <1% | 1,336 | $41K | |
| 86762 | <1% | 2,346 | $38K | |
| 87205 | <1% | 1,692 | $38K | |
| 80061 | Lipid panel | <1% | 3,093 | $38K |
| 11721 | <1% | 2,068 | $37K | |
| 86361 | <1% | 1,515 | $36K | |
| 93505 | <1% | 28 | $36K | |
| 17311 | <1% | 95 | $35K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 24 | $34K |
| 87653 | <1% | 561 | $34K | |
| 72197 | <1% | 127 | $34K | |
| 73562 | <1% | 891 | $33K | |
| 0064A | <1% | 471 | $33K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 9,922 | $33K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,288 | $32K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 439 | $32K |
| 92235 | <1% | 203 | $32K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,982 | $31K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 35,176 | $31K |
| 87340 | <1% | 3,112 | $31K | |
| 86803 | <1% | 1,938 | $31K | |
| 73630 | <1% | 732 | $31K | |
| 96900 | <1% | 996 | $31K | |
| 97124 | <1% | 1,182 | $31K | |
| 64400 | <1% | 175 | $31K | |
| 0003A | <1% | 354 | $30K | |
| 31575 | <1% | 160 | $29K | |
| 88142 | <1% | 2,057 | $28K | |
| 86769 | <1% | 707 | $28K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 600 | $28K |
| 52000 | <1% | 51 | $28K | |
| 87799 | <1% | 1,323 | $27K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 58 | $27K |
| 73030 | <1% | 469 | $26K | |
| 82565 | <1% | 38,300 | $25K | |
| 94729 | <1% | 328 | $24K | |
| 84100 | <1% | 15,451 | $24K | |
| 94010 | <1% | 481 | $24K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 65 | $23K |
| 81001 | <1% | 19,520 | $23K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,836 | $22K |
| 86901 | <1% | 3,673 | $22K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 230 | $21K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,551 | $21K |
| 92587 | <1% | 165 | $21K | |
| G0239 | Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring) | <1% | 1,108 | $21K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 124 | $20K |
| 80321 | <1% | 93 | $20K | |
| Q3014 | Telehealth originating site facility fee | <1% | 17,637 | $20K |
| 97165 | <1% | 447 | $20K | |
| 64566 | <1% | 90 | $20K | |
| 0124A | <1% | 602 | $20K | |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | <1% | 14 | $19K |
| 95886 | <1% | 451 | $19K | |
| 77470 | <1% | 13 | $19K | |
| 86832 | <1% | 850 | $18K | |
| 82947 | <1% | 49,607 | $17K | |
| 96415 | <1% | 55 | $17K | |
| 85652 | <1% | 4,825 | $16K | |
| 80051 | <1% | 37,065 | $16K | |
| 82784 | <1% | 1,426 | $16K | |
| 84403 | <1% | 1,211 | $16K | |
| 20611 | <1% | 68 | $15K | |
| 84153 | <1% | 1,020 | $15K | |
| 92586 | <1% | 1,850 | $15K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 220 | $15K |
| 94760 | <1% | 4,692 | $14K | |
| 83540 | <1% | 869 | $14K | |
| 97162 | <1% | 1,599 | $14K | |
| 97113 | <1% | 469 | $14K | |
| 0054A | <1% | 414 | $14K | |
| 76830 | Ultrasound, transvaginal | <1% | 95 | $14K |
| 83020 | <1% | 815 | $13K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 847 | $13K |
| 73564 | <1% | 148 | $12K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 80 | $12K |
| 95811 | <1% | 19 | $12K | |
| 82950 | <1% | 2,781 | $12K | |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | <1% | 39 | $11K |
| 0352U | <1% | 544 | $10K | |
| 77334 | <1% | 64 | $10K | |
| 84520 | <1% | 37,083 | $10K | |
| 86160 | <1% | 490 | $10K | |
| 77336 | <1% | 119 | $10K | |
| 84466 | <1% | 858 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 182 | $10K |
| 77301 | <1% | 15 | $9K | |
| 92250 | <1% | 312 | $8K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 25 | $8K |
| 73110 | <1% | 191 | $8K | |
| 87497 | <1% | 62 | $8K | |
| 82570 | <1% | 1,271 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,278 | $7K |
| 73130 | <1% | 190 | $7K | |
| 82075 | <1% | 5,173 | $7K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 60 | $7K |
| 86833 | <1% | 849 | $7K | |
| 82728 | <1% | 639 | $7K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 752 | $7K |
| 83970 | <1% | 315 | $6K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 679 | $6K |
| 80320 | <1% | 68 | $6K | |
| 11102 | <1% | 15 | $6K | |
| 84439 | <1% | 879 | $6K | |
| 83883 | <1% | 291 | $6K | |
| 73502 | <1% | 107 | $6K | |
| 90480 | <1% | 332 | $6K | |
| 93976 | <1% | 57 | $6K | |
| 0013A | <1% | 63 | $6K | |
| 86704 | <1% | 133 | $6K | |
| 80305 | <1% | 2,075 | $5K | |
| 87077 | <1% | 238 | $5K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 28 | $5K |
| 76942 | <1% | 288 | $5K | |
| 97161 | <1% | 734 | $5K | |
| 84156 | <1% | 1,235 | $5K | |
| 90656 | <1% | 262 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,492 | $5K |
| 91320 | <1% | 281 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 54 | $4K |
| 82043 | <1% | 346 | $4K | |
| 83615 | <1% | 3,435 | $4K | |
| 97164 | <1% | 295 | $4K | |
| 95913 | <1% | 17 | $4K | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 283 | $4K |
| 85730 | <1% | 270 | $4K | |
| 92020 | <1% | 62 | $4K | |
| 50200 | <1% | 21 | $4K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 40 | $4K |
| 86317 | <1% | 152 | $3K | |
| 80069 | <1% | 403 | $3K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 26 | $3K |
| 86480 | <1% | 125 | $3K | |
| 86635 | <1% | 13 | $3K | |
| 86665 | <1% | 91 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 78 | $3K |
| 83013 | <1% | 102 | $3K | |
| J2400 | Injection, chloroprocaine hydrochloride, per 30 ml | <1% | 350 | $3K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 359 | $3K |
| 97163 | <1% | 193 | $3K | |
| 86300 | <1% | 167 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 44 | $2K |
| 86355 | <1% | 128 | $2K | |
| 85046 | <1% | 1,378 | $2K | |
| 84550 | <1% | 4,373 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,680 | $2K |
| 86364 | <1% | 256 | $2K | |
| 76642 | <1% | 18 | $2K | |
| 81002 | <1% | 61 | $2K | |
| 77073 | <1% | 96 | $2K | |
| 84165 | <1% | 982 | $2K | |
| 82951 | <1% | 78 | $2K | |
| 86644 | <1% | 105 | $2K | |
| 69210 | <1% | 32 | $2K | |
| 0071A | <1% | 25 | $2K | |
| 20550 | <1% | 14 | $2K | |
| 86787 | <1% | 105 | $2K | |
| 88112 | <1% | 161 | $2K | |
| 93325 | <1% | 25 | $2K | |
| 58300 | <1% | 12 | $2K | |
| 0072A | <1% | 21 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 17 | $2K |
| 73560 | <1% | 44 | $2K | |
| 82378 | <1% | 318 | $2K | |
| 86828 | <1% | 171 | $2K | |
| 86225 | <1% | 151 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,679 | $2K |
| 86765 | <1% | 13 | $2K | |
| 86708 | <1% | 40 | $2K | |
| 95874 | <1% | 138 | $2K | |
| 83521 | <1% | 662 | $2K | |
| 86255 | <1% | 82 | $2K | |
| 97597 | <1% | 23 | $1K | |
| 16020 | <1% | 20 | $1K | |
| 86141 | <1% | 140 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,288 | $1K |
| 86356 | <1% | 128 | $1K | |
| 84702 | <1% | 96 | $1K | |
| 77077 | <1% | 28 | $1K | |
| 90734 | <1% | 29 | $1K | |
| 84450 | <1% | 337 | $1K | |
| A4649 | Surgical supply; miscellaneous | <1% | 157 | $1K |
| 84480 | <1% | 103 | $1K | |
| 73590 | <1% | 16 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,260 | $1K |
| 82607 | <1% | 136 | $1K | |
| 86696 | <1% | 13 | $1K | |
| 82670 | <1% | 96 | $1K | |
| 86695 | <1% | 13 | $1K | |
| 97760 | <1% | 25 | $1K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 25 | $959.19 |
| 76937 | <1% | 14 | $935.63 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 45 | $928.09 |
| 83605 | <1% | 25 | $925.14 | |
| 36416 | <1% | 2,073 | $897.18 | |
| 97116 | <1% | 136 | $877.89 | |
| 82952 | <1% | 65 | $867.11 | |
| 0450 | Emergency room services | <1% | 17 | $862.04 |
| 90678 | <1% | 24 | $819.54 | |
| 64644 | <1% | 15 | $803.36 | |
| 77300 | <1% | 22 | $795.24 | |
| 90662 | <1% | 95 | $784.57 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,853 | $778.52 |
| 82077 | <1% | 375 | $763.05 | |
| 76857 | <1% | 78 | $735.84 | |
| 90674 | <1% | 18 | $699.26 | |
| 83861 | <1% | 25 | $691.68 | |
| 82977 | <1% | 25 | $687.39 | |
| 86235 | <1% | 96 | $672.43 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 32 | $623.84 |
| 97012 | <1% | 112 | $612.26 | |
| 36591 | <1% | 131 | $602.03 | |
| 84460 | <1% | 338 | $561.90 | |
| 83690 | <1% | 3,386 | $532.27 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 20 | $494.03 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,108 | $478.49 |
| 86706 | <1% | 25 | $441.74 | |
| 97014 | <1% | 381 | $434.52 | |
| 92523 | <1% | 14 | $431.29 | |
| 84703 | <1% | 52 | $396.37 | |
| 92567 | <1% | 39 | $382.88 | |
| 86003 | <1% | 41 | $380.73 | |
| 96119 | <1% | 109 | $379.35 | |
| C1769 | Guide wire | <1% | 362 | $361.87 |
| 90677 | <1% | 14 | $349.20 | |
| 93296 | <1% | 13 | $334.15 | |
| 83014 | <1% | 102 | $331.35 | |
| 85007 | <1% | 29 | $325.13 | |
| 87631 | <1% | 16 | $311.49 | |
| 84080 | <1% | 28 | $301.75 | |
| 86849 | <1% | 29 | $248.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 364 | $239.72 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 102 | $239.72 |
| 86200 | <1% | 73 | $200.85 | |
| 82248 | <1% | 14 | $198.18 | |
| 82746 | <1% | 48 | $187.34 | |
| 64450 | <1% | 13 | $183.66 | |
| 93280 | <1% | 13 | $171.52 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 67 | $169.26 |
| 86038 | <1% | 55 | $150.29 | |
| 86431 | <1% | 70 | $140.62 | |
| 96401 | <1% | 21 | $122.31 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,161 | $120.23 |
| 86807 | <1% | 12 | $114.64 | |
| 97035 | <1% | 44 | $85.25 | |
| 86334 | <1% | 30 | $74.57 | |
| 11045 | <1% | 13 | $68.93 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 12 | $68.78 |
| 82550 | <1% | 16 | $56.50 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 50 | $55.19 |
| 88313 | <1% | 13 | $54.62 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 701 | $49.80 |
| 86645 | <1% | 62 | $46.83 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,404 | $45.97 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,176 | $41.06 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 43 | $34.62 |
| 90837 | Psychotherapy session, about an hour | <1% | 22 | $25.09 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,327 | $19.37 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 232 | $18.65 |
| 0011A | <1% | 44 | $16.94 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,272 | $9.76 |
| 84157 | <1% | 13 | $4.65 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 44 | $3.60 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 849 | $3.43 |
| 82945 | <1% | 13 | $2.33 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 155 | $0.00 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 12 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 641 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 57 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 484 | $0.00 |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 13 | $0.00 |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 41 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 693 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 181 | $0.00 |
| 92557 | 0% | 109 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 27 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 165 | $0.00 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 0% | 13 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 34 | $0.00 |
| 99152 | 0% | 42 | $0.00 | |
| 97811 | 0% | 22 | $0.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 41 | $0.00 |
| 97810 | 0% | 22 | $0.00 | |
| 98940 | 0% | 18 | $0.00 | |
| J2401 | Injection, chloroprocaine hydrochloride, per 1 mg | 0% | 14 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 20 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| E0190 | Positioning cushion/pillow/wedge, any shape or size, includes all components and accessories | 0% | 15 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 120 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 363 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 198 | $0.00 |
| 88342 | 0% | 12 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 68 | $0.00 |
| 99385 | 0% | 13 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 46 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 119 | $0.00 |
| 93320 | 0% | 25 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 20 | $0.00 |
| 94761 | 0% | 108 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 31 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 20 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 54 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 29 | $0.00 |
| 96376 | 0% | 15 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| 0012A | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCONCORDIA, ELIZABETH (PRESIDENT/CEO, UCHEALTH)
| Provider | Location | Paid |
|---|---|---|
| Poudre Valley Health Care INC. | Fort Collins, CO | $19.97M |
| Poudre Valley Health Care INC | Windsor, CO | $11.80M |
| University of Colorado Hospital Authority | Aurora, CO | $3.82M |
| University of Colorado Hospital Authority | Arvada, CO | $1.37M |
| Poudre Valley Health Care INC. | Fort Collins, CO | $1.29M |
| Poudre Valley Health Care INC | Windsor, CO | $1.16M |
| University of Colorado Hospital Authority | Thornton, CO | $800K |
| University of Colorado Hospital Authority | Commerce City, CO | $685K |
| Poudre Valley Health Care INC. | Fort Collins, CO | $441K |
| Poudre Valley Health Care INC. | Aurora, CO | $185K |
| Poudre Valley Health Care INC | Greeley, CO | $136K |
| University of Colorado Hospital Authority | Denver, CO | $2K |
| University of Colorado Hospital Authority | Denver, CO | $1K |
| University of Colorado Hospital Authority | Denver, CO | $409.85 |
| University of Colorado Hospital Authority | Lone Tree, CO | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.